Δ9-Tetrahydrocannabinol Prevents Cardiovascular Dysfunction in STZ-Diabetic Wistar-Kyoto Rats

The aim of this study was to determine if chronic, low-dose administration of a nonspecific cannabinoid receptor agonist could provide cardioprotective effects in a model of type I diabetes mellitus. Diabetes was induced in eight-week-old male Wistar-Kyoto rats via a single intravenous dose of streptozotocin (65 mg kg−1). Following the induction of diabetes, Δ9-tetrahydrocannabinol was administered via intraperitoneal injection (0.15 mg kg−1 day−1) for an eight-week period until the animals reached sixteen weeks of age. Upon completion of the treatment regime, assessments of vascular reactivity and left ventricular function and electrophysiology were made, as were serum markers of oxidative stress and lipid peroxidation. Δ9-Tetrahydrocannabinol administration to diabetic animals significantly reduced blood glucose concentrations and attenuated pathological changes in serum markers of oxidative stress and lipid peroxidation. Positive changes to biochemical indices in diabetic animals conferred improvements in myocardial and vascular function. This study demonstrates that chronic, low-dose administration of Δ9-tetrahydrocannabinol can elicit antihyperglycaemic and antioxidant effects in diabetic animals, leading to improvements in end organ function of the cardiovascular system. Implications from this study suggest that cannabinoid receptors may be a potential new target for the treatment of diabetes-induced cardiovascular disease.

[1]  W. Hager,et al.  and s , 2019, Shallow Water Hydraulics.

[2]  J. Pincemail,et al.  [Oxidative stress]. , 2007, Revue medicale de Liege.

[3]  Gorjan Alagic,et al.  #p , 2019, Quantum information & computation.

[4]  Kenji Suzuki,et al.  Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats. , 2009, Biological & pharmaceutical bulletin.

[5]  E. Herradón,et al.  Vasorelaxation caused by cannabinoids: mechanisms in different vascular beds. , 2008, Current vascular pharmacology.

[6]  E. Abel,et al.  Diabetic cardiomyopathy, causes and effects , 2010, Reviews in Endocrine and Metabolic Disorders.

[7]  Dao-wu Wang,et al.  Abnormalities of K+ and Ca2+ currents in ventricular myocytes from rats with chronic diabetes. , 1995, The American journal of physiology.

[8]  M. Ben Amar,et al.  Cannabinoids in medicine: A review of their therapeutic potential. , 2006, Journal of ethnopharmacology.

[9]  W. Marsden.  I and J , 2012 .

[10]  Sushil K. Jain,et al.  Oxidative stress, insulin signaling, and diabetes. , 2011, Free radical biology & medicine.

[11]  B. Costa,et al.  Beneficial effects of a Cannabis sativa extract treatment on diabetes‐induced neuropathy and oxidative stress , 2009, Phytotherapy research : PTR.

[12]  J. Manson,et al.  Vitamin D and calcium intake in relation to type 2 diabetes in women. , 2006, Diabetes care.

[13]  C. S. Reddy,et al.  Cardioprotective actions of two bioflavonoids, quercetin and rutin, in experimental myocardial infarction in both normal and streptozotocin‐induced type I diabetic rats , 2009 .

[14]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[15]  B. Karlberg,et al.  Methyl malondialdehyde as an internal standard for the determination of malondialdehyde. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[16]  S. O'Sullivan,et al.  Vascular targets for cannabinoids: animal and human studies , 2014, British journal of pharmacology.

[17]  N. Dhalla,et al.  Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants , 2013, Heart Failure Reviews.

[18]  F. Bermúdez-Silva,et al.  Role of cannabinoid CB2 receptors in glucose homeostasis in rats. , 2007, European journal of pharmacology.

[19]  N. Cortas,et al.  Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. , 1990, Clinical chemistry.

[20]  D. Naidoo,et al.  Improved method for plasma malondialdehyde measurement by high-performance liquid chromatography using methyl malondialdehyde as an internal standard. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[21]  I. N. Ponomarenko,et al.  Nitric Oxide Inhibition Simulates the Enhancement of α1Agonist-Induced Vasoconstriction in Diabetes , 1997 .

[22]  D. Bell,et al.  Diabetic cardiomyopathy. , 2003, Diabetes care.

[23]  G. Lopaschuk,et al.  Peroxynitrite impairs cardiac contractile function by decreasing cardiac efficiency. , 1997, The American journal of physiology.

[24]  W. Campbell,et al.  Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. , 1999, The American journal of physiology.

[25]  D. Deutsch,et al.  Production and physiological actions of anandamide in the vasculature of the rat kidney. , 1997, The Journal of clinical investigation.

[26]  R. Ritchie,et al.  Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes , 2012, Diabetologia.

[27]  J. T. Saari,et al.  Malondialdehyde inhibits cardiac contractile function in ventricular myocytes via a p38 mitogen‐activated protein kinase‐dependent mechanism , 2003, British journal of pharmacology.

[28]  R. Sarpong,et al.  Bio-inspired synthesis of xishacorenes A, B, and C, and a new congener from fuscol† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc02572c , 2019, Chemical science.

[29]  A. Garber.  Diabetes and vascular disease , 2000, Diabetes, obesity and metabolism.

[30]  Dhiren P. Shah,et al.  ON OXIDATIVE STRESS AND DIABETIC COMPLICATIONS , 2013 .

[31]  M. Cotter,et al.  Effects of diabetes and treatment with the antioxidant α-lipoic acid on endothelial and neurogenic responses of corpus cavernosum in rats , 1999, Diabetologia.

[32]  Michael Brownlee,et al.  The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.

[33]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[34]  C. Chavkin,et al.  Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes , 1995, Neuroscience Letters.

[35]  M. Mittleman,et al.  The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. , 2013, The American journal of medicine.

[36]  W. B. S. Compan.  Antioxidant and Triglyceride-Low ering Effects of Vitamin E Associated With the Prevention of Abnormalities in the Reactivity and Morphology of Aorta From Streptozotocin-Diabetic Rats , 1997 .

[37]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[38]  Jun Ren,et al.  Phytoestrogenic Isoflavones Daidzein and Genistein Reduce Glucose‐Toxicity‐Induced Cardiac Contractile Dysfunction in Ventricular Myocytes , 2004, Endocrine research.

[39]  Thomas de Quincey.  [C] , 2000, The Works of Thomas De Quincey, Vol. 1: Writings, 1799–1820.

[40]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[41]  Ahmad Esmaillzadeh,et al.  Effects of calcium–vitamin D co-supplementation on glycaemic control, inflammation and oxidative stress in gestational diabetes: a randomised placebo-controlled trial , 2014, Diabetologia.

[42]  A. Fenning,et al.  Resveratrol Prevents Cardiovascular Complications in the SHR/STZ Rat by Reductions in Oxidative Stress and Inflammation , 2015, BioMed research international.

[43]  D. Kendall,et al.  Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. , 2005, Biochemical and biophysical research communications.

[44]  S. Steffens,et al.  Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies , 2012, British journal of pharmacology.

[45]  C. Kanakis,et al.  The electrophysiological effects of delta-9-tetrahydrocannabinol (cannabis) on cardiac conduction in man. , 1977, American heart journal.

[46]  I. Megson,et al.  Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. , 2008, Antioxidants & redox signaling.

[47]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[48]  M. Mustafa,et al.  Effect of quercetin on altered vascular reactivity in aortas isolated from streptozotocin-induced diabetic rats. , 2006, Diabetes research and clinical practice.

[49]  K. Mackie,et al.  Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension , 2004, Circulation.

[50]  K. Schmid,et al.  The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. , 2003, Heart, lung & circulation.

[51]  N. Maulik,et al.  Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. , 2007, Free radical biology & medicine.

[52]  A. Veves,et al.  Cannabidiol Attenuates Cardiac Dysfunction , Oxidative Stress , Fibrosis , and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy , 2017 .

[53]  W. Campbell,et al.  Cannabinoid CB 1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca 2 1 channel current , 1999 .

[54]  F. Mach,et al.  Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice , 2005, Nature.

[55]  S. Subramanian,et al.  Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic β‐cell dysfunction in streptozotocin‐nicotinamide‐induced diabetic rats , 2010, Journal of cellular physiology.

[56]  N. Dhalla,et al.  Subcellular remodeling and heart dysfunction in chronic diabetes. , 1998, Cardiovascular research.

[57]  E. Abel,et al.  Molecular mechanisms of diabetic cardiomyopathy , 2014, Diabetologia.